232 related articles for article (PubMed ID: 15190513)
1. Acute promyelocytic leukemia as a paradigm for targeted therapy.
Tallman MS
Semin Hematol; 2004 Apr; 41(2 Suppl 4):27-32. PubMed ID: 15190513
[TBL] [Abstract][Full Text] [Related]
2. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.
Zhou GB; Zhang J; Wang ZY; Chen SJ; Chen Z
Philos Trans R Soc Lond B Biol Sci; 2007 Jun; 362(1482):959-71. PubMed ID: 17317642
[TBL] [Abstract][Full Text] [Related]
3. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
4. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
5. [Arsenic trioxide in combination with all-trans retinoic acid for acute promyelocytic leukemia: a systematic review and meta-analysis].
Xu SN; Chen JP; Liu JP; Xia Y
Zhong Xi Yi Jie He Xue Bao; 2009 Nov; 7(11):1024-34. PubMed ID: 19912733
[TBL] [Abstract][Full Text] [Related]
6. What is the role of arsenic in newly diagnosed APL?
Tallman MS
Best Pract Res Clin Haematol; 2008 Dec; 21(4):659-66. PubMed ID: 19041605
[TBL] [Abstract][Full Text] [Related]
7. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells.
Shao W; Fanelli M; Ferrara FF; Riccioni R; Rosenauer A; Davison K; Lamph WW; Waxman S; Pelicci PG; Lo Coco F; Avvisati G; Testa U; Peschle C; Gambacorti-Passerini C; Nervi C; Miller WH
J Natl Cancer Inst; 1998 Jan; 90(2):124-33. PubMed ID: 9450572
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports.
Lin CP; Huang MJ; Chang IY; Lin WY
Leuk Lymphoma; 2000 Jun; 38(1-2):191-4. PubMed ID: 10811462
[TBL] [Abstract][Full Text] [Related]
9. New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation.
Kitamura K; Kiyoi H; Yoshida H; Tobita T; Takeshita A; Ohno R; Naoe T
Cancer Chemother Pharmacol; 1997; 40 Suppl():S36-41. PubMed ID: 9272132
[TBL] [Abstract][Full Text] [Related]
10. Acute promyelocytic leukemia: from highly fatal to highly curable.
Wang ZY; Chen Z
Blood; 2008 Mar; 111(5):2505-15. PubMed ID: 18299451
[TBL] [Abstract][Full Text] [Related]
11. Arsenic and apoptosis in the treatment of acute promyelocytic leukemia.
Look AT
J Natl Cancer Inst; 1998 Jan; 90(2):86-8. PubMed ID: 9450562
[No Abstract] [Full Text] [Related]
12. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
13. The PML-RARalpha fusion protein and targeted therapy for acute promyelocytic leukemia.
Jing Y
Leuk Lymphoma; 2004 Apr; 45(4):639-48. PubMed ID: 15160934
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis of all-trans retinoic acid-linked arsenic trioxide treatment for acute promyelocytic leukemia.
Chen L; Wang J; Hu X; Xu X
Hematology; 2014 Jun; 19(4):202-7. PubMed ID: 24074286
[TBL] [Abstract][Full Text] [Related]
15. Acute promyelocytic leukemia: where did we start, where are we now, and the future.
Coombs CC; Tavakkoli M; Tallman MS
Blood Cancer J; 2015 Apr; 5(4):e304. PubMed ID: 25885425
[TBL] [Abstract][Full Text] [Related]
16. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
Che-Pin Lin ; Huang MJ; Chang IY; Lin WY; Sheu YT
Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
[TBL] [Abstract][Full Text] [Related]
17. Acute promyelocytic leukemia in childhood.
Gregory J; Feusner J
Curr Oncol Rep; 2009 Nov; 11(6):439-45. PubMed ID: 19840521
[TBL] [Abstract][Full Text] [Related]
18. Treatment of acute promyelocytic leukemia and other hematologic malignancies with arsenic trioxide: review of clinical and basic studies.
Liu P; Han ZC
Int J Hematol; 2003 Jul; 78(1):32-9. PubMed ID: 12894848
[TBL] [Abstract][Full Text] [Related]
19. Addition of Arsenic Trioxide into Induction Regimens Could Not Accelerate Recovery of Abnormality of Coagulation and Fibrinolysis in Patients with Acute Promyelocytic Leukemia.
Zhang Y; Wu S; Luo D; Zhou J; Li D
PLoS One; 2016; 11(1):e0147545. PubMed ID: 26812490
[TBL] [Abstract][Full Text] [Related]
20. Differentiating agents in pediatric malignancies: all-trans-retinoic acid and arsenic in acute promyelocytic leukemia.
Calleja EM; Warrell RP
Curr Oncol Rep; 2000 Nov; 2(6):519-23. PubMed ID: 11122887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]